PT  - JOURNAL ARTICLE
AU  - Mwananyanda, Lawrence
AU  - Gill, Christopher J.
AU  - MacLeod, William
AU  - Kwenda, Geoffrey
AU  - Pieciak, Rachel
AU  - Mupila, Zachariah
AU  - Mupeta, Francis
AU  - Forman, Leah
AU  - Ziko, Luunga
AU  - Etter, Lauren
AU  - Thea, Donald
TI  - COVID-19 deaths detected in a systematic post-mortem surveillance study in Africa
AID  - 10.1101/2020.12.22.20248327
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.22.20248327
4099  - http://medrxiv.org/content/early/2020/12/24/2020.12.22.20248327.short
4100  - http://medrxiv.org/content/early/2020/12/24/2020.12.22.20248327.full
AB  - Objectives Limited SARS CoV 2 testing in many African countries has constrained availability of data on the impact of COVID-19 (CV19). To address this gap, we conducted a systematic post-mortem surveillance study to directly measure the fatal impact of CV19 in an urban African population.Design We enrolled deceased individuals at the University Teaching Hospital (UTH) Morgue in Lusaka, Zambia. We obtained nasopharyngeal swabs for testing via reverse-transcriptase quantitative PCR (RT-qPCR) against the SARS-2 Coronavirus. We stratified deaths by CV19 status, by location, age, sex, and underlying risk factors.Setting UTH is Zambia’s largest tertiary care referral hospital and its morgue registers ∼80% of Lusaka’s deaths.Participants Participants of all ages were enrolled if within 48 hours of death and if the next of kin or representative provided written informed consent.Results We enrolled 372 participants between June and September 2020, and had PCR results for 364 (99.5%). CV19 was detected in 70/364 (19.2%). The median age for CV19+ deaths was 48 years (IQR 36-72 years) and 70% were male. Most CV19+ deaths (51/70, 72.8%) occurred in the community; none had been tested for CV19 antemortem. Among the 19/70 facility deaths, six were tested antemortem. Among the 52/70 CV19 deaths with symptoms data, 44/52 had typical symptoms of CV19 (cough, fever, shortness of breath), of whom only five were tested antemortem. We identified CV19 among seven children; only one had been tested antemortem. The proportion of CV19+ deaths increased with age, but 75.7% of CV19+ deaths were aged <60 years. The five most common co-morbidities among CV19+ deaths were: tuberculosis (31.4%); hypertension (27.1%); HIV/AIDS (22.9%); alcohol use (17.1%); and diabetes (12.9%).Conclusions Contrary to expectations, CV19+ deaths were common in Lusaka. The majority occurred in the community where testing capacity is lacking. Yet few who died at facilities were tested, despite presenting with typical symptoms of CV19. Therefore, CV19 cases were under reported because testing was rarely done, not because CV19 was rare. If our data are generalizable, the impact of CV19 in Africa has been vastly underestimated.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis was not a clinical trialFunding StatementThe work was funded by the Bill & Melinda Gates Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research protocol was approved by the ethical review boards at Boston University Medical Center and The University of Zambia.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe are willing to share our data